da Cunha, Mélanie Faria
Pranke, Iwona
Sassi, Ali
Schreiweis, Christiane
Moriceau, Stéphanie
Vidovic, Dragana
Hatton, Aurélie
Carlon, Mariane Sylvia
Creste, Geordie
Berhal, Farouk
Prestat, Guillaume
Freund, Romain
Odolczyk, Norbert
Jais, Jean Philippe
Gravier-Pelletier, Christine
Zielenkiewicz, Piotr
Jullien, Vincent
Hinzpeter, Alexandre
Oury, Franck
Edelman, Aleksander
Sermet-Gaudelus, Isabelle
Funding for this research was provided by:
Vaincre La Mucoviscidose (RF20180502264)
Agence Nationale de la Recherche (ANR-13-BSV1-0019-02)
Article History
Received: 1 August 2021
Accepted: 28 February 2022
First Online: 12 April 2022
Competing interests
: MFDC, IP, AS, CS, SM, DV, MC, G C, FB, GP, RF, CHC, NO, JPJ, CGP, PZ, AH, FO, and AE do not declare any potential financial and non-financial competing interest. ISG declares following fundings from Vertex Pharmaceuticals: Innovation Award funding program 2016, 2017 and 2019. She was PI in clinical trials from Vertex Pharmaceuticals and took part to scientific advisory boards organized by Vertex Pharmaceuticals, Eloxx and Proteostasis Therapeutics.